A patent review of topoisomerase 1 inhibitors (2021-present).
1/5 보강
[INTRODUCTION] Among the different topoisomerases, essential enzymes that play an important role in DNA processes such as replication and transcription, type I enzymes are targets of particular clinic
APA
Fuertes M, Martín-Encinas E, et al. (2026). A patent review of topoisomerase 1 inhibitors (2021-present).. Expert opinion on therapeutic patents, 36(1), 25-40. https://doi.org/10.1080/13543776.2025.2579073
MLA
Fuertes M, et al.. "A patent review of topoisomerase 1 inhibitors (2021-present).." Expert opinion on therapeutic patents, vol. 36, no. 1, 2026, pp. 25-40.
PMID
41236376 ↗
Abstract 한글 요약
[INTRODUCTION] Among the different topoisomerases, essential enzymes that play an important role in DNA processes such as replication and transcription, type I enzymes are targets of particular clinical importance for anticancer and antiparasitic drugs. Bearing this in mind, in the last 5 years specific inhibitors, both poison and suppressor types, have been patented for this target.
[AREAS COVERED] This review covers the patent literature on topoisomerase 1 inhibitors and their application published between late 2020-present.
[EXPERT OPINION] TOP1 inhibitors are being used in combination with synergistic therapies within a multimodal approach, including targeted therapies, adaptive immunotherapy, and the blockade of DNA repair mechanisms. Advances in drug delivery systems, especially antibody-drug conjugates (ADCs), are revolutionizing chemotherapy by enabling localized and tumor-specific drug release. In addition to traditional inhibitors like irinotecan and topotecan, new agents such as deruxtecan and govitecan have been approved, expanding therapeutic options. Moreover, small new molecules with more promising clinical potential are being developed.
[AREAS COVERED] This review covers the patent literature on topoisomerase 1 inhibitors and their application published between late 2020-present.
[EXPERT OPINION] TOP1 inhibitors are being used in combination with synergistic therapies within a multimodal approach, including targeted therapies, adaptive immunotherapy, and the blockade of DNA repair mechanisms. Advances in drug delivery systems, especially antibody-drug conjugates (ADCs), are revolutionizing chemotherapy by enabling localized and tumor-specific drug release. In addition to traditional inhibitors like irinotecan and topotecan, new agents such as deruxtecan and govitecan have been approved, expanding therapeutic options. Moreover, small new molecules with more promising clinical potential are being developed.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.